From: An in vitro toolbox to accelerate anti-malarial drug discovery and development
Compound | B/Pa | Haematocrit (Gender) |
---|---|---|
Ionized or partially ionized bases at physiological pH | ||
 Cycloguanil | 0.71 ± 0.07 | 0.48 (M) |
 Doxycyclin | 0.78 ± 0.06 | 0.43 (M) |
 Pyronaridine | 9.0 ± 0.83 | 0.48 (M) |
 Proguanil | 3.30 ± 0.14 | 0.46 (M) |
 Primaquine | 0.82 ± 0.07 | 0.44 (M) |
 Chloroquine | 3.5 ± 0.09 | 0.42 (F) |
 Chlorproguanil | 3.3 ± 0.38 | 0.43 (M) |
 Azithromycin | 1.6 ± 0.19 | 0.48 (M) |
 AQ-13 | 3.15 ± 0.20 | 0.42 (M) |
 Desethylamodiaquine | 3.26 ± 0.35 | 0.50 (M) |
 Quinine | 0.67 ± 0.02 | 0.44 (M) |
 Clindamycin | 0.61 ± 0.04 | 0.42 (M) |
 KAF156 | 1.3 ± 0.02 | 0.42 (F) |
 M5717 | 1.3 ± 0.02 | 0.42 (F) |
 OZ277 | 1.10 ± 0.10 | 0.46 (M) |
 Mefloquine | 1.1 ± 0.07 | ~ 0.43 (M) |
 Amodiaquine | 1.1 ± 0.18 | ~ 0.43 (M) |
 NPC1161B | 1.09 ± 0.07 | 0.44 (M) |
 Ferroquine | 1.6 ± 0.15 | ~ 0.43 (M) |
 Naphthoquine | 1.14 ± 0.10 | ~ 0.43 (M) |
 Tafenoquine | 1.3 ± 0.04 | ~ 0.43 (M) |
 MMV253 | 1.0 ± 0.05 | ~ 0.43 (M) |
 MMV052 | 1.6 ± 0.14 | ~ 0.43 (M) |
 Piperaquine | 0.57 ± 0.05 | ~ 0.43 (M) |
 Halofantrine | 0.68 ± 0.06 | 0.43 (M) |
 TDD-E209 | 0.51 ± 0.08 | 0.44 (M) |
 Lumefantrine | 0.48 ± 0.09 | 0.48 (M) |
Ionized acids at physiological pH | ||
 Sulfadoxine | 0.57 ± 0.03 | 0.46 (M) |
 Sulfamethoxazole | 0.65 ± 0.07 | 0.43 (M) |
 Artesunate | CNDb | 0.44 (M) |
 Atovaquone | 0.52 ± 0.03 | 0.44 (M) |
Zwitterionic or partially zwitterionic at physiological pH | ||
 P218 | 0.56 ± 0.03 | ~ 0.43 (M) |
 JPC3210 | 0.54 ± 0.04 | ~ 0.43 (M) |
Neutral at physiological pH | ||
 Dapsone | 1.1 ± 0.06 | 0.43 (M) |
 Dihydroartemisinin | CNDb | 0.42 (M) |
 DSM421 | 0.53 ± 0.03 | 0.44 (M) |
 Pyrimethamine | 0.84 ± 0.03 | 0.43 (M) |
 MMV048 | 0.77 ± 0.03 | 0.42 (F) |
 Artemisone | CNDb | 0.44 (M) |
 Artemether | CNDb | 0.42 (M) |
 SJ733 | 0.72 ± 0.02 | 0.42 (F) |
 DSM265 | 0.54 ± 0.02 | 0.44 (M) |
 KAE609 | 0.66 ± 0.04 | 0.42 (F) |
 OZ439 | 0.78 ± 0.05 | 0.44 (M) |
 ELQ300 | 0.53 ± 0.05 | 0.44 (M) |